<![CDATA[Hansa Biopharma Interim report January-September 2022]]>· Total Revenue of SEK 67m in the third quarter 2022
· Positive reimbursement decisions received in Poland and Scotland
· $70 million raised in non-dilutive financing
· Imlifidase included in ESOT guidelines published in Transplant International

Link Preview Image
Hansa Biopharma Interim report January-September 2022 | Hansa Biopharma

favicon

(www.hansabiopharma.com)

]]>https://dev.proinvestor.com/forum/topic/444394/hansa-biopharma-interim-report-january-september-2022RSS for NodeMon, 29 Jun 2026 21:02:27 GMTThu, 20 Oct 2022 04:03:13 GMT60<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Fri, 21 Oct 2022 13:27:37 GMT]]>Hansa Biopharma: Klaus Sindahl, Head of Investor Relations presenterar på Redeye Investor AW - Göteborg 20 oktober 2022:

Just a moment...

favicon

(www.redeye.se)

(Redeye)

]]>https://dev.proinvestor.com/forum/post/9478237https://dev.proinvestor.com/forum/post/9478237Fri, 21 Oct 2022 13:27:37 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 13:07:41 GMT]]>Som jeg skrev tidligere, så lugter amerikanerne blod, og shorter Big time.

]]>https://dev.proinvestor.com/forum/post/9478238https://dev.proinvestor.com/forum/post/9478238Thu, 20 Oct 2022 13:07:41 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 12:29:41 GMT]]>Ja, de er dygtig 🙂

]]>https://dev.proinvestor.com/forum/post/9478240https://dev.proinvestor.com/forum/post/9478240Thu, 20 Oct 2022 12:29:41 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 11:55:45 GMT]]>Morgan Stanley Europe har foreløbig netto-solgt 116.200 aktier;-)

]]>https://dev.proinvestor.com/forum/post/9478243https://dev.proinvestor.com/forum/post/9478243Thu, 20 Oct 2022 11:55:45 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 10:24:22 GMT]]>Investor Road Show Presentation Q3 2022:

Link Preview Image
Events and presentations | Hansa Biopharma

Latest presentations by Hansa Biopharma and upcoming and past investors events.

favicon

(www.hansabiopharma.com)

https://www.hansabiopharma.com/files/Presentations/2022/20221020_HNSA_-_Q3_2022_Road_Show_Presentation_FINAL.pdf

CC er igang!

]]>https://dev.proinvestor.com/forum/post/9478233https://dev.proinvestor.com/forum/post/9478233Thu, 20 Oct 2022 10:24:22 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 08:16:47 GMT]]>Tålmod. Det er bare at samle op!

Jeg venter gerne til 2023-24-25.

]]>https://dev.proinvestor.com/forum/post/9478235https://dev.proinvestor.com/forum/post/9478235Thu, 20 Oct 2022 08:16:47 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 06:29:00 GMT]]>Ja, men desværre har tilliden til aktien været tæt på et nulpunkt gennem længere tid.

Investorerne venter på, at se "penge i kassen" og ikke det modsatte kvartal efter kvartal. Derfor har det været en populær aktie hos shorterne i de seneste år. Men forhåbentlig ser vi en positiv resultat-vending i løbet af 2023.

Hansa Biopharma rapporterer et driftsresultat på SEK -140 millioner (-148) for tredje kvartal af 2022. Falder p.t. ca 6%.

]]>https://dev.proinvestor.com/forum/post/9478239https://dev.proinvestor.com/forum/post/9478239Thu, 20 Oct 2022 06:29:00 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 05:07:00 GMT]]>"The current valuation is attractive for investors prepared to look into 2023 and beyond. Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600) is under review. Hansa's Q3 result will likely trigger a positive reaction mainly based on very modest valuations, secured access to growth capital and a promising outlook over the next 12 to 24 months."

(Redeye)

]]>https://dev.proinvestor.com/forum/post/9478231https://dev.proinvestor.com/forum/post/9478231Thu, 20 Oct 2022 05:07:00 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 05:05:33 GMT]]>Hansa Biopharma: Q3 Launch and Genetic exploratory progress

Just a moment...

favicon

(www.redeye.se)

(Redeye)

Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.

]]>https://dev.proinvestor.com/forum/post/9478230https://dev.proinvestor.com/forum/post/9478230Thu, 20 Oct 2022 05:05:33 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 04:19:01 GMT]]>I forhold til "Consensus estimates" så er indtægterne (nettoomsætningen) absolut til den rigtig side.

Revenue: Q3 2022 SEKm 67.1 - 9M 2022 SEKm 123.8.

]]>https://dev.proinvestor.com/forum/post/9478232https://dev.proinvestor.com/forum/post/9478232Thu, 20 Oct 2022 04:19:01 GMT<![CDATA[Reply to Hansa Biopharma Interim report January-September 2022 on Thu, 20 Oct 2022 04:08:33 GMT]]>Upcoming milestones and news flow

2022 Anti-GBM: Initiation of phase 3 study

2022 NiceR: Completion of GLP tox studies

H2 2022 AMR Phase 2 study: First data read out

H2 2022 U.S. Kidney transplantation: Complete enrollment

H2 2022/H1 2023 GBS Phase 2 study: Complete enrollment

H1 2023 U.S. Kidney transplantation: Complete randomization

H2 2023 GBS Phase 2 study: First data read out

2023 Long-term follow-up data 5-years out in kidney transplantation

2024 Kidney transplantation US: BLA submission

]]>https://dev.proinvestor.com/forum/post/9478236https://dev.proinvestor.com/forum/post/9478236Thu, 20 Oct 2022 04:08:33 GMT